CHICAGO (GenomeWeb) – PreventionGenetics, a CLIA-certified DNA testing laboratory, said today that it has integrated its testing and interpretation services with with FDNA's Face2Gene next-generation phenotyping application suite.
Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses, based on a database of more than 10,000 rare disease syndromes. Marshfield, Wisconsin-based PreventionGenetics said this integration would help improve the diagnostic ability of its testing by finding genetic variants relevant to specific diseases and each patient's clinical phenotype.
"Bringing FDNA's artificial intelligence and facial analysis technologies to PreventionGenetics and other leading labs is facilitating a new age in precision medicine," FDNA CEO Dekel Gelbman said in a statement. "With this integration, clinicians can identify malfunctioning genetics for their patients faster, opening the door to therapy."
FDNA has struck other integration deals recently. In September, FDNA announced that it would integrate Face2Gene with AmbryPort 2.0, a clinical ordering system from Ambry Genetics.